NASDAQ:MBRX

Moleculin Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy MBRX

*Your capital is at risk

$2.21

-0.0700 (-3.07%)

At Close: Jul 13, 2026

Moleculin Biotech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.93. In total, the insiders bought 11.58M and sold 21.61K MBRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.93
● Buy	11.58M shares
● Sell	21.61K shares
76% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Jun 23, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.93. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (76% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 22, 2026 Sell	Common Stock F-InKind	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	41 Value: $128
Jun 22, 2026 Buy	Common Stock M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	174 Value: $543
Jun 22, 2026 Buy	Restricted Stock Units M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	174 Value: $543
Jun 22, 2026 Buy	Restricted Stock Units M-Exempt	Picker Donald H Chief Science Officer	Officer	71 Value: $222
Jun 22, 2026 Buy	Common Stock M-Exempt	Picker Donald H Chief Science Officer	Officer	71 Value: $222
Jun 22, 2026 Sell	Common Stock F-InKind	Picker Donald H Chief Science Officer	Officer	21 Value: $66
Jun 22, 2026 Buy	Restricted Stock Units M-Exempt	Klemp Walter V CEO And President	CEO / President	360 Value: $1K
Jun 22, 2026 Buy	Common Stock M-Exempt	Klemp Walter V CEO And President	CEO / President	360 Value: $1K
Jun 22, 2026 Sell	Common Stock F-InKind	Klemp Walter V CEO And President	CEO / President	88 Value: $275
Jun 20, 2026 Sell	Common Stock F-InKind	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	31 Value: $89
Jun 20, 2026 Buy	Common Stock M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	109 Value: $241
Jun 20, 2026 Buy	Restricted Stock Units M-Exempt	Foster Jonathan P. Chief Financial Officer	C-Suite Officer	109 Value: $241
Jun 20, 2026 Sell	Common Stock F-InKind	Klemp Walter V CEO And President	CEO / President	37 Value: $107
Jun 20, 2026 Buy	Restricted Stock Units M-Exempt	Picker Donald H Chief Science Officer	Officer	44 Value: $97
Jun 20, 2026 Buy	Common Stock M-Exempt	Picker Donald H Chief Science Officer	Officer	44 Value: $97
Jun 20, 2026 Sell	Common Stock F-InKind	Picker Donald H Chief Science Officer	Officer	13 Value: $37
Jun 20, 2026 Buy	Restricted Stock Units M-Exempt	Klemp Walter V CEO And President	CEO / President	150 Value: $332
Jun 20, 2026 Buy	Common Stock M-Exempt	Klemp Walter V CEO And President	CEO / President	150 Value: $332
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Cermak Elizabeth Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock Options (right to buy) A-Award	Yan Joy Director	Director	150 000 Value: $73.5K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Klemp Walter V CEO And President	CEO / President	830 000 Value: $406.7K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Picker Donald H Cso	Officer	200 000 Value: $98.0K
Nov 12, 2025 Buy	Performance Based Restricted Stock Units A-Award	Picker Donald H Cso	Officer	200 000 Value: $97.5K
Nov 12, 2025 Buy	Performance Based Restricted Stock Units A-Award	Foster Jonathan P. EVP & CFO	C-Suite Officer	400 000 Value: $195.0K
Nov 12, 2025 Buy	Stock option (right to buy) A-Award	Foster Jonathan P. EVP & CFO	C-Suite Officer	600 000 Value: $294.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MOLECULIN BIOTECH INC

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...

Read Full Profile Here